Compare GASS & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GASS | LXEO |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.4M | 348.7M |
| IPO Year | 2005 | 2023 |
| Metric | GASS | LXEO |
|---|---|---|
| Price | $8.14 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $20.30 |
| AVG Volume (30 Days) | 93.5K | ★ 1.5M |
| Earning Date | 11-24-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.55 | $2.55 |
| 52 Week High | $10.55 | $10.99 |
| Indicator | GASS | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 31.81 | 49.56 |
| Support Level | $7.69 | $2.98 |
| Resistance Level | $8.24 | $3.68 |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 8.58 | 97.01 |
StealthGas Inc is an international shipping transportation company. It owns liquefied petroleum gas (LPG) pressurized carriers and provides international seaborne transportation services to LPG producers and users, as well as crude oil and product carriers to oil producers, refineries, and commodities traders. The company carriers carry various petroleum gas products in liquefied forms, such as propane, butane, butadiene, isopropane, propylene, and vinyl chloride monomer, which are all byproducts of the production of crude oil and natural gas.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.